ABSTRACT
The present study extends our previous work regarding new antifolates for Mycobacterium avium (MAC) dihydrofolate reductase (DHFR). The objectives of this study were to synthesize and test new derivatives in the general class of 2,4-diamino-5-methyl-5-deazapteridines in an effort to improve solubility and selectivity for the MAC DHFR, while maintaining lack of selectivity for the human DHFR. New 6-[2', 5'-dialkoxyphenyl) methyl]-substituted DMDP analogs were synthesized as previously described. Three clinical isolates of MAC (NJ211, NJ3404, and NJ168) and M. tuberculosis H37Ra (MTB) were used to evaluate the new derivatives. A previously described colorimetric (alamarBlue(R)) microdilution broth assay was used to determine minimal inhibitory concentrations (MIC). Purified recombinant human (rDHFR), MAC rDHFR, and MTB rDHFR were used in a validated enzyme assay to obtain IC(50) values and to determine selectivity ratios (SR) for the derivatives. For the MAC strains, the MICs ranged from < 0.25 to > 16 microg/mL. The most active derivative against MAC was SRI-20920 which had MICs of 0.25, 0.25, and 8 microg/mL for the three strains, respectively. The most selective derivative was SRI-20730 with IC(50s) of 29 and 67,781 nM for MAC rDHFR and hDHFR, respectively, and a SR of 2,337. MICs for MTB ranged from 4 to >64 microg/mL and the SR, in general, ranged from 0.32 to 2.5. These results further substantiate the utility of this group of DMDP derivatives for selective activity against MAC.
Subject(s)
Folic Acid Antagonists/chemistry , Folic Acid Antagonists/pharmacology , Mycobacterium avium/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Folic Acid Antagonists/chemical synthesis , Folic Acid Antagonists/classification , Humans , Molecular Structure , Mycobacterium tuberculosis/drug effects , Structure-Activity Relationship , Tetrahydrofolate Dehydrogenase/metabolismABSTRACT
Mycobacterium avium complex (MAC) is resistant to trimethoprim, an inhibitor of bacterial dihydrofolate reductase (DHFR). A previously identified selective inhibitor of MAC DHFR, SRI-8858, was shown to have synergistic activity in combination with dapsone and sulfamethoxazole, two drugs that inhibit bacterial dihydropteroate synthase.
Subject(s)
Dihydropteroate Synthase/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Folic Acid Antagonists/pharmacology , Mycobacterium avium Complex/drug effects , Pyrimidines/pharmacology , Drug Synergism , Microbial Sensitivity TestsABSTRACT
The preparation of a new 2-carbamoyl pteridine, its activity data against FtsZ from M. tuberculosis (Mtb), and in vitro antibacterial data against Mtb strain H37Ra are presented.
Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Cytoskeletal Proteins/antagonists & inhibitors , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Pteridines/chemistry , Pteridines/pharmacology , Bacterial Proteins/physiology , Cytoskeletal Proteins/physiologyABSTRACT
The emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (MTB) and the continuing pandemic of tuberculosis emphasizes the urgent need for the development of new anti-tubercular agents with novel drug targets. The recent structural elucidation of the mycobacterial cell wall highlights a large variety of structurally unique components that may be a basis for new drug development. This publication describes the synthesis, characterization, and screening of several octyl Galf(beta,1-->5)Galf and octyl Galf(beta,1-->6)Galf derivatives. A cell-free assay system has been utilized for galactosyltransferase activity using UDP[14C]Galf as the glycosyl donor, and in vitro inhibitory activity has been determined in a colorimetric broth microdilution assay system against MTB H37Ra and three clinical isolates of Mycobacterium avium complex (MAC). Certain derivatives showed moderate activities against MTB and MAC. The biological evaluation of these disaccharides suggests that more hydrophobic analogues with a blocked reducing end showed better activity as compared to totally deprotected disaccharides that more closely resemble the natural substrates in cell wall biosynthesis.
Subject(s)
Disaccharides/chemistry , Disaccharides/metabolism , Galactosyltransferases/metabolism , Mycobacterium/enzymology , Antitubercular Agents/chemistry , Antitubercular Agents/metabolism , Antitubercular Agents/pharmacology , Biochemistry/methods , Carbohydrate Conformation , Disaccharides/pharmacology , Drug Evaluation, Preclinical , Inhibitory Concentration 50 , Mycobacterium/drug effects , Structure-Activity RelationshipABSTRACT
The appearance multi-drug resistant Mycobacterium tuberculosis (MTB) throughout the world has prompted a search for new, safer and more active agents against tuberculosis. Based on studies of the biosynthesis of mycobacterial cell wall polysaccharides, octyl 5-O-(alpha-D-arabinofuranosyl)-alpha-D-arabinofuranoside analogues were synthesized and evaluated as inhibitors for M. tuberculosis and Mycobacterium avium. A cell free assay system has been used for the evaluation of these disaccharides as substrates for mycobacterial arabinosyltransferase activity.
Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/metabolism , Disaccharides/chemistry , Disaccharides/metabolism , Mycobacterium tuberculosis/enzymology , Pentosyltransferases/metabolism , Antitubercular Agents/pharmacology , Carbohydrate Conformation , Disaccharides/pharmacology , Drug Evaluation, Preclinical , Inhibitory Concentration 50 , Mycobacterium avium/drug effects , Mycobacterium avium/enzymology , Mycobacterium tuberculosis/drug effects , Pentosyltransferases/antagonists & inhibitors , Structure-Activity RelationshipABSTRACT
Twenty-five 1-deaza-7,8-dihydropteridine derivatives were screened for antimycobacterial activity against Mycobacterium tuberculosis strain H37Ra and three Mycobacterium avium clinical isolates (serovar 1, 4 or 6). Antibacterial activity was determined with a colorimetric microdilution broth assay. Seventeen of the compounds inhibited growth in the range >1.28 to Subject(s)
Anti-Bacterial Agents/chemistry
, Anti-Bacterial Agents/pharmacology
, Mycobacterium avium/drug effects
, Mycobacterium tuberculosis/drug effects
, Pteridines/chemistry
, Pteridines/pharmacology
, Anti-Bacterial Agents/chemical synthesis
, Cell Division/drug effects
, Colorimetry
, Drug Evaluation, Preclinical
, Folic Acid Antagonists/chemical synthesis
, Folic Acid Antagonists/chemistry
, Folic Acid Antagonists/pharmacology
, Humans
, Microbial Sensitivity Tests
, Mycobacterium avium/enzymology
, Mycobacterium avium/growth & development
, Mycobacterium tuberculosis/growth & development
, Pteridines/chemical synthesis
, Quantitative Structure-Activity Relationship
, Tetrahydrofolate Dehydrogenase/metabolism
ABSTRACT
Development of new antimycobacterial agents for Mycobacterium avium complex (MAC) infections is important particularly for persons coinfected with human immunodeficiency virus. The objectives of this study were to evaluate the in vitro activity of 2, 4-diamino-5-methyl-5-deazapteridines (DMDPs) against MAC and to assess their activities against MAC dihydrofolate reductase recombinant enzyme (rDHFR). Seventy-seven DMDP derivatives were evaluated initially for in vitro activity against one to three strains of MAC (NJ168, NJ211, and/or NJ3404). MICs were determined with 10-fold dilutions of drug and a colorimetric (Alamar Blue) microdilution broth assay. MAC rDHFR 50% inhibitory concentrations versus those of human rDHFR were also determined. Substitutions at position 5 of the pteridine moiety included -CH(3), -CH(2)CH(3), and -CH(2)OCH(3) groups. Additionally, different substituted and unsubstituted aryl groups were linked at position 6 through a two-atom bridge of either -CH(2)NH, -CH(2)N(CH(3)), -CH(2)CH(2), or -CH(2)S. All but 4 of the 77 derivatives were active against MAC NJ168 at concentrations of < or =13 microg/ml. Depending on the MAC strain used, 81 to 87% had MICs of < or =1.3 microg/ml. Twenty-one derivatives were >100-fold more active against MAC rDHFR than against human rDHFR. In general, selectivity was dependent on the composition of the two-atom bridge at position 6 and the attached aryl group with substitutions at the 2' and 5' positions on the phenyl ring. Using this assessment, a rational synthetic approach was implemented that resulted in a DMDP derivative that had significant intracellular activity against a MAC-infected Mono Mac 6 monocytic cell line. These results demonstrate that it is possible to synthesize pteridine derivatives that have selective activity against MAC.
Subject(s)
Anti-Infective Agents/chemical synthesis , Folic Acid Antagonists/chemical synthesis , Mycobacterium/drug effects , Mycobacterium/enzymology , Pteridines/chemical synthesis , Pyrimidines/chemical synthesis , Tetrahydrofolate Dehydrogenase/metabolism , Anti-Bacterial Agents , Anti-Infective Agents/pharmacology , Cell Line , Cell Survival , Colony Count, Microbial , Folic Acid Antagonists/pharmacology , Humans , Macrophages/drug effects , Magnetic Resonance Spectroscopy , Microbial Sensitivity Tests , Monocytes/drug effects , Monocytes/microbiology , Pteridines/pharmacology , Pyrimidines/pharmacology , Recombinant Proteins/pharmacology , Structure-Activity RelationshipABSTRACT
Ethambutol is an established front-line agent for the treatment of tuberculosis, and is also active against Mycobacterium avium infection. However, this agent exhibits toxicity, and is considered to have low potency. The action of ethambutol on the mycobacterial cell wall, particularly the arabinan, and comparison of the structure of ethambutol with several of the cell-wall saccharides, suggested that ethambutol-saccharide hybrids might lead to agents with a more selective mechanism of action. To this end, eight ethambutol-saccharide hybrids were synthesized and screened against M. tuberculosis and several clinical isolates of M. avium.
Subject(s)
Antitubercular Agents/chemical synthesis , Ethambutol/analogs & derivatives , Ethambutol/chemical synthesis , Monosaccharides/chemistry , Mycobacterium avium/drug effects , Mycobacterium tuberculosis/drug effects , Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Cell Wall/drug effects , Ethambutol/chemistry , Ethambutol/pharmacology , Indicators and Reagents , Monosaccharides/pharmacology , Mycobacterium avium/physiology , Mycobacterium tuberculosis/physiology , Structure-Activity RelationshipABSTRACT
The biochemically unique structures of sugar residues in the outer cell wall of Mycobacterium tuberculosis (MTB) make the pathways for their biosynthesis and utilization attractive targets for the development of new and selective anti-tubercular agents. A cell-free assay system for galactosyltransferase activity using UDP[14C]Gal as the glycosyl donor, as well as an in vitro colorimetric broth micro-dilution assay system, were used to determine the activities of three beta-D-gal(f)(1-->4)-alpha-L-rham(p) octyl disaccharides as substrates and antimycobacterial agents respectively. The cell-free enzymatic studies using compounds 8 and 10 suggested that these disaccharides bind to and are effective substrates for a putative mycobacterial galactosyltransferase. The modified acceptor 8 was found to be a slower but prolonged binder as compared to the less substituted analogue 10 as evidenced by their Km and Vmax values. Moderate antimycobacterial activity was observed with compounds 8 and 9 against MTB H37Ra and three clinical isolates of Mycobacterium avium complex (MAC).
Subject(s)
Anti-Bacterial Agents/pharmacology , Antitubercular Agents/pharmacology , Disaccharides/pharmacology , Galactosyltransferases/metabolism , Mycobacterium avium/drug effects , Mycobacterium tuberculosis/drug effects , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/metabolism , Antitubercular Agents/chemical synthesis , Antitubercular Agents/metabolism , Carbohydrate Sequence , Colorimetry , Disaccharides/chemical synthesis , Disaccharides/metabolism , Enzyme Inhibitors/pharmacology , Galactosyltransferases/antagonists & inhibitors , Microbial Sensitivity Tests , Molecular Sequence Data , Substrate SpecificityABSTRACT
Twelve lipophilic 2,4-diamino-5-methyl-5-deazapteridine derivatives and trimethoprim were evaluated for activity against Mycobacterium tuberculosis and Mycobacterium avium in vitro. Six of the compounds had MICs of < or =12.8 mg/L and < or =1.28 mg/L against M. tuberculosis and M. avium, respectively; trimethoprim MICs were >128 mg/L and >12.8 but < or =128 mg/L, respectively. Two compounds, with either a 2-methyl-5-methoxy phenyl or 2-methoxy-5-trifluoromethyl phenyl linked at the 6-position of the deazapteridine moiety by a CH2NH bridge, had MICs of < or =0.13 mg/L against M. avium; the two compounds also had apparent I50 values for dihydrofolate reductase of 2 and 8 nM, respectively, compared with an I50 of 400 nM with trimethoprim. Four of the compounds were selectively toxic to mycobacteria as compared with Vero cells. These results demonstrated that lipophilic antifolates can be synthesized which are more active against mycobacteria than trimethoprim and which possess selective toxicity.
Subject(s)
Folic Acid Antagonists/pharmacology , Mycobacterium avium Complex/drug effects , Mycobacterium tuberculosis/drug effects , Pteridines/pharmacology , Trimethoprim/pharmacology , Animals , Cell Survival/drug effects , Chlorocebus aethiops , Folic Acid Antagonists/chemistry , Humans , Microbial Sensitivity Tests , Mycobacterium avium-intracellulare Infection/microbiology , Tetrahydrofolate Dehydrogenase/metabolism , Trimethoprim/chemistry , Tuberculosis/microbiology , Vero CellsABSTRACT
A series of hydrolytically-stable aza analogs of arabinofuranose was prepared and evaluated against Mycobacterium tuberculosis and M. avium. The compounds were designed to mimic the putative arabinose donor involved in biogenesis of the essential cell wall polysaccharide, arabinogalactan. Though most compounds displayed little activity in cell culture, one compound showed significant activity in infected macrophage models.
Subject(s)
Anti-Bacterial Agents/pharmacology , Arabinose/pharmacology , Mycobacterium avium Complex/drug effects , Mycobacterium tuberculosis/drug effects , Animals , Anti-Bacterial Agents/chemistry , Arabinose/chemistry , Cell Line , Humans , Macrophages/microbiology , Mice , Microbial Sensitivity Tests , Molecular Structure , Mycobacterium avium Complex/isolation & purification , Mycobacterium tuberculosis/isolation & purificationABSTRACT
Dihydrofolate reductase is an essential bacterial enzyme necessary for the maintenance of intracellular folate pools in a biochemically active reduced state. In this report, the Mycobacterium avium folA gene was identified by functional genetic complementation, sequenced, and expressed for the first time. It has an open reading frame of 543 bp with a G + C content of 73%. The translated polypeptide sequence shows 58% identity to the consensus sequence of the conserved regions from eight other bacterial dihydrofolate reductases. Recombinant M. avium dihydrofolate reductase was expressed actively in Escherichia coli, and SDS-PAGE analysis revealed a 20 kDa species, agreeable with that predicted from the polypeptide sequence:
Subject(s)
Genes, Bacterial , Mycobacterium avium Complex/enzymology , Mycobacterium avium Complex/genetics , Tetrahydrofolate Dehydrogenase/genetics , Amino Acid Sequence , Base Sequence , Cloning, Molecular , Conserved Sequence , DNA Primers/genetics , DNA, Bacterial/genetics , Escherichia coli/genetics , Gene Expression , Molecular Sequence Data , Molecular Weight , Open Reading Frames , Polymerase Chain Reaction , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Tetrahydrofolate Dehydrogenase/chemistry , Tetrahydrofolate Dehydrogenase/metabolismABSTRACT
The Mono Mac 6 (MM6) human monocytic cell line was evaluated with the established J774 murine macrophage cell line to ascertain its effectiveness in determining the intracellular activities of antimycobacterial drugs. Cells were infected with Mycobacterium tuberculosis H37Ra and treated with drug concentrations corresponding to the MICs, as well as to threefold higher than and threefold less than the MICs. Changes in CFU were compared after 7 days to determine significant differences between treated and nontreated groups. The results suggest that MM6 will make a useful model for testing the intracellular activities of antituberculosis drugs.
Subject(s)
Antitubercular Agents/pharmacology , Macrophages/microbiology , Monocytes/microbiology , Mycobacterium tuberculosis/drug effects , Animals , Cell Line , Cell Survival , Colony Count, Microbial , Humans , Macrophages/drug effects , Mice , Microbial Sensitivity Tests , Monocytes/drug effectsSubject(s)
Antitubercular Agents/pharmacology , Ethambutol/pharmacology , Glycosyltransferases/drug effects , Mycobacterium avium Complex/drug effects , Mycobacterium tuberculosis/drug effects , In Vitro Techniques , Mycobacterium avium Complex/enzymology , Mycobacterium avium Complex/metabolism , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/metabolism , Phospholipids/metabolismABSTRACT
Spirohydantoin mustard (SHM), a central nervous system directed nitrogen mustard with anticancer activity, was metabolized in the presence of mouse liver postmitochondrial supernatant (9000g fraction) to a nonpolar alkylating metabolite. The metabolite was isolated by thin-layer chromatography of chloroform or ethyl acetate extracts of incubation mixtures, and its structure was established by mass spectral analysis, synthesis, and cochromatography. The metabolite, spirohydantoin aziridine, was mutagenic for Salmonella typhimurium TA1535 in the Ames assay but inactive as an antitumor agent against P388 leukemia in vivo.
Subject(s)
Antineoplastic Agents/chemical synthesis , Aziridines/chemical synthesis , Azirines/chemical synthesis , Mutagens/chemical synthesis , Animals , Aziridines/pharmacology , Aziridines/therapeutic use , Biotransformation , Drug Evaluation, Preclinical , Leukemia P388/drug therapy , Mice , Microsomes, Liver/metabolism , Mutagenicity Tests , Mutation , Salmonella typhimurium/drug effects , Structure-Activity RelationshipABSTRACT
The mechanism for an enhanced effect of Aroclor 1254-induced Sprague-Dawley rat liver 9,000 x g supernatant (S9) microsome preparation on the mutagenicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-N-nitrosourea (CCNU), and 2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose (chlorozotocin) for Salmonella typhimurium strain TA1535 was studied. Although all three compounds were direct-acting mutagens, rat liver S9 increased the mutagenic response to BCNU, CCNU, and chlorozotocin. The enhanced mutagenic effect was independent of NADPH. Heat-denatured S9 enhanced the mutagenicity of BCNU and CCNU, but not that of chlorozotocin. Mutagenic enhancement, however, was less than that observed with untreated S9. The substitution of extractable S9 lipid and bovine serum albumin for S9 in the reaction mixture resulted in an enhanced mutagenicity of CCNU with little or no effect on BCNU or chlorozotocin mutagenicity. These results suggest that the enhanced mutagenicity of CCNU, and possibly that of BCNU, in the presence of S9 was due in part to nonspecific factors that are present in the S9 preparation.
Subject(s)
Carmustine/toxicity , Cyclophosphamide/toxicity , Lomustine/toxicity , Microsomes, Liver/metabolism , Mutagens , Mutation , Nitrosourea Compounds/toxicity , Streptozocin/analogs & derivatives , Animals , Aroclors/pharmacology , Biotransformation , Mutagenicity Tests , Rats , Salmonella typhimurium/drug effects , Streptozocin/toxicityABSTRACT
The metabolism of spirohydantoin mustard (SHM), a central nervous system-directed nitrogen mustard with reported anticancer activity, was studied using both the Salmonella/mammalian microsome mutagenicity assay and radiolabeled drug. SHM had little or no mutagenic activity by itself but was metabolized to a mutagen(s) in the presence of mouse postmitochondrial liver fraction (9000 g supernatant, S9). Metabolism was NADPH-dependent and was enhanced with phenobarbital-induced S9. Both SHM and mutagen(s) were extractable in chloroform. Studies using [14C]SHM, uniformly labeled on the bis(2-chloroethyl)amino group, and thin-layer chromatography (TLC) of chloroform extracts of liver S9 incubation mixtures indicated the formation of a single major metabolite fraction that contained a direct-acting mutagen. Chloroform extracts of both blood and brain from BDF1 mice injected i.p. with SHM (60 mg/kg) were found to be mutagenic in the absence of S9. Also, TLC of chloroform extracts of brain taken 15 min after i.p. injection of [14C]SHM suggested the presence of SHM and the mutagenic metabolite. These results suggest that the mutagenic metabolite may have a significant role in the mechanism of action of SHM.
Subject(s)
Alkylating Agents/metabolism , Hydantoins/metabolism , Liver/enzymology , Mutagens/metabolism , Nitrogen Mustard Compounds/metabolism , Animals , Biotransformation , Female , In Vitro Techniques , Kinetics , Male , Mice , Phenobarbital/pharmacology , Salmonella typhimurium/geneticsABSTRACT
The mutagenicity of 4,4'-bis(dimethylamino)benzophenone (Michler's ketone, MK, CAS No. 90-94-8) and 4,4'-methylenebis(N,N-dimethyl)benzamine (reduced Michler's ketone, RMK, CAS No. 101-61-1) for Salmonella typhimurium strain TA100 was compared using activated 9000 X g (S9) liver supernatants from 2 animal species. RMK, but not MK, was mutagenic when incubated with phenobarbital-induced B6D2F1 mouse or Osborne-Mendel rat-liver S9. The mutagenic response for RMK was linear at doses from 1 to 33 micrograms/plate. A higher percentage of RMK and MK became irreversibly bound to mouse-liver macromolecules than to rat-liver macromolecules when incubated at 37 degrees C in the presence of reduced nicotinamide adenine dinucleotide phosphate.
Subject(s)
Aniline Compounds/toxicity , Benzhydryl Compounds/toxicity , Benzophenones/toxicity , Mutagens , Aniline Compounds/metabolism , Animals , Benzhydryl Compounds/metabolism , Benzophenones/metabolism , DNA/metabolism , In Vitro Techniques , Liver/metabolism , Male , Mice , Microsomes, Liver/metabolism , NADP/metabolism , Oxidation-Reduction , Protein Binding , Rats , Salmonella typhimurium/geneticsABSTRACT
Isophosphoramide mustard was synthesized and was found to demonstrate activity essentially comparable to cyclophosphamide and ifosfamide against L1210 and P388 leukaemia. Lewis lung carcinoma, mammary adenocarcinoma 16/C, ovarian sarcoma M5076, and colon tumour 6A, in mice and Yoshida ascitic sarcoma in rats. At doses less than, or equivalent to, the LD10, isophosphoramide mustard retained high activity against cyclophosphamide-resistant L1210 and P388 leukaemias, but was less active against intracerebrally-implanted P388 leukaemia while cyclophosphamide produced a 4 log10 tumour cell reduction. It was also less active (one log10 lower cell kill) than cyclophosphamide against the B16 melonoma. Metabolism studies on ifosfamide in mice identified isophosphoramide mustard in blood. In addition, unchanged drug, carboxyifosfamide, 4-ketoifosfamide, dechloroethyl cyclophosphamide, dechloroethylifosfamide, and alcoifosfamide were identified. The latter 4 metabolites were also identified in urine from an ifosfamide-treated dog. In a simulated in vitro pharmacokinetic experiment against L1210 leukaemia in which drugs were incubated at various concentrations for various times, both 4-hydroxycyclophosphamide and isophosphoramide mustard exhibited significant cytoxicity at concentration times time values of 100-1000 micrograms X min ml-1, while acrolein was significantly cytotoxic at 10 micrograms X min ml-1. Treatment of mice with drug followed by L1210 cells demonstrated a shorter duration of effective levels of cytotoxic activity for isophosphoramide mustard and phosphoramide mustard in comparison with cyclophosphamide and ifosfamide. Isophosphoramide mustard and 2-chloroethylamine, a potential hydrolysis product of isophosphoramide mustard and carboxyifosfamide, were less mutagenic in the standard Ames test than the 2 corresponding metabolites of cyclophosphamide [phosphoramide mustard and bis(2-chloroethyl)amine].
Subject(s)
Antineoplastic Agents/therapeutic use , Cyclophosphamide/analogs & derivatives , Cyclophosphamide/therapeutic use , Ifosfamide/analogs & derivatives , Neoplasms, Experimental/drug therapy , Phosphoramide Mustards , Adenocarcinoma/drug therapy , Animals , Antineoplastic Agents/metabolism , Cell Survival , Colonic Neoplasms/drug therapy , Female , Ifosfamide/metabolism , Ifosfamide/therapeutic use , Leukemia, Experimental/drug therapy , Male , Mammary Neoplasms, Experimental/drug therapy , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , Rats , Sarcoma, Yoshida/drug therapyABSTRACT
Studies on the in vivo and in vitro disposition of 4,4'-[14C]-methylenebis(N,N-dimethyl)benzamine (reduced Michler's ketone, RMK) were performed. Osborne-Mendel rats retained, after 24 hr, 78% of a p.o. dose of [14C]RMK. At 24 hr after an i.p. dose, fat, liver, and intestine represented major sites for deposition of radioactivity. The major urinary metabolite of RMK, representing 36% of the total radioactivity recovered in the urine, was N,N'-diacetyl-4,4'-(hydroxymethylene)dianiline. In vitro microsomal metabolism of RMK involved demethylation. Products included N,N-dimethyl-4,4'-methylenedianiline, N,N'-dimethyl-4,4'-methylenedianiline, N-methyl-4,4'-methylenedianiline, and 4,4'-methylenedianiline, representing 44.7, 5.3, 11.8, and 6.9%, respectively, of the total radioactivity recovered from the reaction mixture. Although none of the microsomal metabolites was a direct-acting mutagen in the standard Salmonella typhimurium assay, all could be activated to mutagens when incubated with 9000 X g liver supernatants and reduced nicotinamide adenine dinucleotide phosphate. The activation of 4,4'-methylenedianiline to a mutagen suggests that the methyl groups of RMK are not required for the conversion of RMK to a reactive electrophile.